Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides
- 7 November 2019
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (19), 1866-1869
- https://doi.org/10.1056/nejmcibr1910023
Abstract
Insulin resistance is a precursor to and accelerant of coexisting conditions such as type 2 diabetes, atherosclerosis, and nonalcoholic liver disease. A recent study of mouse models implicates elevated levels of ceramide and their effect on mitochondrial function in the mediation of cellular insulin resistance.Keywords
This publication has 6 references indexed in Scilit:
- Serine and Lipid Metabolism in Macular Disease and Peripheral NeuropathyThe New England Journal of Medicine, 2019
- Targeting a ceramide double bond improves insulin resistance and hepatic steatosisScience, 2019
- CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondria! Fragmentation in ObesityCell, 2019
- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic DiseasesCell Metabolism, 2017
- Ceramides – Lipotoxic Inducers of Metabolic DisordersTrends in Endocrinology & Metabolism, 2015
- Role of ceramides in nonalcoholic fatty liver diseaseTrends in Endocrinology & Metabolism, 2012